Featured News

The findings of the Research Opportunities in Celiac Disease Consensus Workshop, sponsored by the CDF, were published as a Research Roadmap for NIH.

On August 24, Rep. Betty McCollum launched the bipartisan Celiac Disease Caucus. We look forward to continuing to work with Rep. McCollum and the Caucus to support innovative research and advance legislation that will ease the suffering of celiac patients.

Please take one minute to email your Members of Congress to make it easier and safer for those with celiac disease to purchase food items by requiring labels to list the presence of barley and rye, in addition to wheat.

Please take ONE MINUTE to contact your Members of Congress, using our simple, pre-populated form, to make it easier and safer for individuals with celiac disease by disclosing if foods contain rye and barley, in addition to wheat.

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.

We are pleased to share that CEO Marilyn Geller will be presenting as the Patient Advocate at the March 18-19 National Institute of Allergy and Infectious Diseases Accelerating Progress in Celiac Disease Workshop. We encourage you to register to attend this seminal virtual meeting.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Celiac Disease Foundation’s article, “New Legislation Aims to Extend Nutrition Care to Chronic Conditions” was featured in Future of Personal Health.

Patients Who Have Participated In a Celiac Disease Clinical Trial Needed for 2021 Patient Education & Advocacy Summit.

Concern has been expressed in the celiac disease community that the FDA’s temporary food labeling requirements during COVID-19 apply to gluten. The FDA confirmed that the introduction of unlabeled gluten is not allowed in regulated food products.